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A gene fusion that links the COOH-terminal 349 amino acids of penicillin-binding protein 3 (60 kDa) of 
E.coli to the NH,terminus of fi-galactosidase has been constructed. The fusion protein (38.5 kDa) retains 
the ability to bind benzylpenicillin with high affinity, establishing that the penicillin-binding domain (and 
presumably the penicillin-sensitive transpeptidase activity) of this high molecular mass penicillin-binding 
protein is located on a COOH-terminal functional domain. 
Escherichia coli Penicillin-binding protein Gene furion &Lactam antibiotic Peptidoglycan . 
Transglycosylase-transpeptiakse 
1. INTRODUCTION 
Penicillin-binding proteins (PBPs) and ,&lac- 
tamases are two classes of enzymes that interact 
with penicillin [ 1,2]. The PBPs are involved in pep- 
tidoglycan synthesis and are inhibited by penicillin, 
whereas the &lactamases de-toxify penicillin by 
hydrolysing it to penicilloic acid. In Escherichiu 
coli the higher molecular mass penicillin-binding 
proteins are the killing targets for &lactam an- 
tibiotics [ 11, and are believed to be bifunctional en- 
zymes catalyzing both the penicillin-insensitive 
peptidoglycan transglycosylase reaction and the 
penicillin-sensitive transpeptidase reaction [3-61. 
The lower molecular mass PBPs catalyse the D- 
alanine carboxypeptidase reaction and are non- 
essential for bacterial growth [1,2]. The class A 
and class C fl-lactamases, and the low molecular 
mass PBPs, are serine enzymes in which penicillin 
(and peptidoglycan substrates in the case of PBPs) 
acylates an active site serine residue that is located 
close to the NHz-terminus of the proteins [7-91. 
The higher molecular mass PBPs are also pre- 
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sumed to be ‘serine enzymes’ but this has yet to be 
demonstrated. 
Sequence comparisons of high molecular mass 
PBPs, low molecular mass PBPs, and class A ,L% 
lactamases have identified one small region of 
similarity between all these proteins ([ 1, lo], un- 
published). In the low molecular mass PBPs, and 
in the &lactamases, this region occurs just to the 
NHz-terminal side of the active site serine, i.e., 
very close to the NHz-terminus of these enzymes. 
In the high molecular mass bifunctional PBPs, this 
region occurs towards the middle of the primary 
sequence (e.g., residues 261-277 in PBP 3) and we 
have suggested that the penicillin-sensitive trans- 
peptidase domain of these PBPs extends from the 
middle of the proteins towards the COOH-termin- 
us and that the transglycosylase domain is NH2- 
terminal [ 1,101. We show here, using gene fusions, 
that a protein which contains only the COOH- 
terminal 349 residues of PBP 3 of E. coli retains 
the ability to bind penicillin with high affinity. 
Constructions of this type may allow the produc- 
tion of soluble penicillin-binding domains that are 
suitable for X-ray analysis of the penicillin-binding 
site of a membrane-bound killing target for 
penicillin. 
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2. MATERIALS AND METHODS 
E. coli JMlOl was used in ail experiments ill]. 
The PBP 3 gene was obtained from pLC26-6 of the 
collection of Clark and Carbon [12,13]. The 
plasmid vector pLG339 [14] and the phage vector 
M13mp8 [1 l] have been described, and pteH8 and 
pteH9 are analogues of the vectors pUC8 and 
pUC9 [ 151 in which the Ap’ gene has been replaced 
by Km’ (unpublished). 
Techniques for the purification and manipula- 
tion of DNA have been described. Restriction en- 
donucleases were obtained from Boehringer or 
from ~ersh~ Internation~ and were used ac- 
cording to the recommendation f the suppliers. 
E. coli JMlOl (pPHl53) was grown in Luria 
broth and expression from the Zac promoter was 
induced by the addition of isopropylthiogalac- 
toside (IPTG, Sigma) to a final concentration of 1 
mM. The assay of PBPs was carried out using 
freeze-thawed bacteria and [3H]benzylpenicillin 
(27 Ci/mmol, kindly provided by Dr P.J. Cassidy 
of Merck Sharp and Dohme, Rahway, NJ, USA) 
as in [16]. Fractionation of bacterial cells into solu- 
ble (cytoplasm and periplasm) and cell envelope 
fractions was carried out as in 1171. 
An estimate of the affinity of the &alactosi- 
dase-PBP 3 fusion protein for benxylpenicillin was 
carried out as in [17] except hat crude extracts of 
bacteria were used. E. coli JMlOl (pPH153) that 
had been induced with IPTG were resuspended in 
ice-cold 50 mM sodium phosphate buffer (PH 7.0) 
at 2x 10” bacteria/ml and were disrupted by 
sonication (OOC). Unbroken bacteria and debris 
were removed by centrifugation at10000 xg for 20 
min at 2°C and the su~rnat~t was used as a 
crude extract co~t~~ng cell envelope, periplas- 
mic, and cytoplasmic fractions. 
3. RESULTS 
The PBP3 gene (p&B) has been sequenced in
[ 181. A P&I site is located at a position correspon- 
ding to amino acids 240/241 and divides the coding 
region at the predicted junction between the trans- 
glycosylase and transpeptidase domains. To con- 
firm the location of the penicillin-sensitive trans- 
peptidase domain, and in an attempt to produce a 
soluble fragment of PBP3 that retains penicillin- 
binding activity and which might be suitable for X- 
180 
ray studies, we have utilized the PstI site to create 
an in-phase fusion to @-galactosidase, The coding 
region of the g&B gene was obtained as a 26W 
base pair (bp} PvuII fragment from pLC26-6 of 
the collection of Clark and Carbon [12,18] and was 
cloned into the SmaI site of the replicative form of 
M13mp8 to produce M13mp8/PBP3A (fig.1). The 
gene was subcloned from the Ml3 recombinant in- 
to pLG339 to produce pPHlO5 (fig.l), and a 
1448-bp P&I-Hi&III fragment, encoding the 
CGOH-terminal region of PBP 3, was obtained 
from pPH105 and was inserted between the PstI 
and W&II sites of pteH8 to produce pPH153 
(fig. 1). 
E. coli JMlOl (pPH153) should express a fusion 
protein (38.5 kDa), under the control of the lac 
promoter, which is comprised of the first 6 amino 
acids of fl-galactosidase, followed by 5 amino acids 
encoded by the multiple cloning region of the vec- 
tor, and residues 240-588 of PBP 3 (fig.2). In the 
absence of IPTG the pattern of PBPs in E. coli 
JMlOl (pPH153) was identical to that in the parent 
strain but in the presence of IPTG a new PBP ap- 
peared that had the predicted molecular mass of 
the PBP 3 fusion protein (fig.3). This protein was 
identified as the fusion product since its expression 
was under the control of the iac promoter and it 
was not made by cells carrying the vector plasmid 
or by constructs (e.g., pPH154) that contained the 
same fragment of the PBP3 gene cloned in the op- 
posite (inappropriate) o~entation i  pteH9 (fig-f). 
The amount of ~3~b~zyl~cillin bound to 
the fusion protein was 150-200% of that bound to 
PBP 5 (fig.3). E. coli contains about 1800 mole- 
cules of PBP 5 per bacterium [17], and therefore 
about 3000 molecules of the fusion protein per 
bacterium were detected by the PBP assay. This 
level is far below that expected for a protein ex- 
pressed from the iac promoter and the la& 
ribosome-binding site on a high copy number vec- 
tor, suggesting that only a portion of the fusion 
protein that was synthesized was being detected by 
the PBP assay. The sensitivity of the fusion protein 
to proteolysis was examined by pre-labelling cells 
with [3H]benzylpenicillin, adding a 200-fold excess 
of unlabelled benxylpenicillin, and following the 
disappearance of the labelled fusion protein during 
in~bation at 37°C. After 30 min incubation there 
was no significant loss of the labelled fusion pro- 
tein. The addition of the protease inhibitor, p- 
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Fig.1. Construction of a lacZ-pbpB fusion. The PBP 3 gene @bpB) was obtained on a 2.6kb P&I fragment from 
the Clarke and Carbon plasmid pLC26-6 1181 and was inserted into M13mp8 to produce Ml3mp8/FBP3A. The gene 
was subcioned into pLCi339 [X4] and a 14Wbp &&HindIII fragment was obtained from the resulting piasmid and 
was inserted into pteH8. A second construction (pPH154) was made that contained the same 1404bp fragment inserted 
in the opposite orientation by cloning into pteH9. 
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12 3 4 5 6 7 8 9 10 11 240 241 242 243 244 587 588 
(MET)TRR MET ILE TRR ASN SER ARC GLY SER VAL ASP LEU GLN ALA LRU VAL . . . . . . ARG SER * 
ATG ACC ATG ATT ACG AAT ‘NC! CGG GGA ‘RX! GE! GAC CTG CAG GCG C!l’G GTT . . . . . a AGA TCG TAA 
Pat1 
Fig.2. The sequence across the kc&pbpB fusion junction in pPH153. Amino acids l-6 are derived from tacZ, residues 
7-11 are encoded by the multiple cloning region of the vector, and residues 240-588 are from the pbpB gene. 
A B c D 
Fig!3. Detection of a penicillin-binding & alactosidase- 
PBP 3 fusion protein. E. coti JMlOl (pPH154) (A,B) 
and JMlOl (pPHl53) (C,D) were grown in Luria broth 
to a cell density of 5 x lO’/ml. Part of each culture was 
removed and IPTG was added to a final concentration 
of 1 mh4 and the cultures were shaken for a further hour 
at 37°C. The bacteria from 0.5 ml of each culture were 
pelleted in an Eppendorf centrifuge for 2 min, the super- 
natant was removed, and the cells were r~us~nd~ in 
20~1 of 50 m&I sodium phosphate buffer (PH 7.0). After 
two cycles of freeze-thawing in a dry ice-ethanol bath, 
5 pl of [3H]benzylpenicillin (27 Wmmol) were added to 
give a final concentration of 50 prg/ml. After 10 min at 
30°C the binding was terminated by the addition of 25 
pl of SDS gel solublliser buffer [17] and the PBPs were 
fractionated on a 12% SDS ~1y~~I~ide gel and were 
detected by fluorography for 3 days at - 70°C [17]. The 
arrow shows the position of the &galactosidase-PBP 3 
fusion protein. 
p~~nylmethylsulfonyl fluoride (1.2 mM), had no 
effect on the amount of the fusion protein detected 
by the PBP assay. Proteolysis is therefore not the 
major cause for the unexpectedly low levels of the 
fusion protein. 
The possibility that the activity of the protein 
was unstable was examined by taking an aliquot of 
E. coli JMlOl (pPH153) that had been induced 
with IPTG, resuspending the cells in 50 mM 
sodium phosphate buffer (pH 7.0) and pre-incu- 
bating the bacteria t 37’C prior to the addition of 
13H]~~l~~ci~n. The half-life of the penicillin- 
binding activity of the fusion protein was less than 
1 min at 37°C. The relatively low level of the fu- 
sion protein that we observed is therefore due to 
the very rapid inactivation of the protein so that 
only a fraction of that synthesized is detected by 
the PBP assay. The stability of the protein was 
higher at 30°C and increased levels could be ob- 
tained in cells grown and assayed at this temper- 
ature .
Measurement of the affinity of the fusion pro- 
tein for [3H]benzylpeniciIlin was complicated by 
the loss of activity of the protein during the assay. 
The ~n~ntrations of radioactive be~l~~cillin 
required to obtain 50% saturation of the fusion 
protein and the normal PBP 3 were, however, in- 
distinguishable (not shown). 
PBP 3 is located in the cytoplasmic membrane 
and is synthesized asa preprotein with an NHz-ter- 
minal signaI peptide [ 181. The fusion of the 
CGGH-terminal part of PBP3 to the NHz-termin- 
us of Bgalactosidase would therefore be expected 
to result in the appearance of the fusion protein in 
the cytoplasm. The instability of the fusion protein 
made it difficult to convincingly demonstrate its 
cellular location. However, experiments in which 
the fusion protein was labelled with i3H]ben- 
zylpenicillin before cell fractionation indicated 
that the protein was equally distributed between 
182 
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the cytoplasmic and cell envelope fractions where- 
as the normal PBP 3 was exclusively found in the 
cell envelope fraction. Further experiments with 
more stable fusion proteins are needed to un- 
ambiguously demonstrate he cellular location and 
solubility properties of the protein. 
4. DISCUSSION 
The properties of the PBP 3 fusion protein 
establish that the whole polypeptide chain that 
constitutes the ~~cillin-binding site is contained 
within amino acids 240-588. The removal of the 
NHz-terminal240 amino acids does not appear to 
substantially alter the affinity of PBP 3 for ben- 
zylpenicillin although it has a drastic effect on 
the stability of the protein. The reason for the de- 
creased stability of the protein is unknown. - - 
The active site residue of PBP 3 that is acylated 
by penicillin must also be located between residues 
240 and 588. This contrasts trikingly with the fin- 
dings with all of the class A and class C ,&lactam- 
ases, and the D-alanine carboxypeptidases, where 
the acylated amino acid is a serine residue located 
close to the N&-terminus [7-91. Strong candidates 
for the active site serine residues of PBP lA, PBP 
1B and PBP 3 have been obtained by comparing 
the amino acid sequences of these PBPs with the 
sequences around the active site serine residues of 
D-alanine carboxypeptidases and @-lactamases (in
preparation). In each of these high molecular mass 
PBPs the assigned active site serine occurs towards 
the middle of the primary sequence and in PBP 3 
the assignment of serine-307 has been supported by 
site-directed mutagenesis (in prep~ation). 
The ~ptidoglyc~ transpeptidase activity may 
also be contained on the PBP 3 fusion protein but 
direct assay of tr~speptidase activity in this 
unstable protein is not possible. Our results are 
therefore consistent with the suggestion that the 
penicillin-sensitive transpeptidase activity is locat- 
ed on a COOH-terming functional domain. One 
obvious possibility is that the transglycosylase do- 
main of PBP 3 is located within the NHz-terminal 
240 residues but there is at present no information 
on this matter. 
The organisation of high molecular mass PBPs 
in the cytoplasmic membrane has not been studied. 
A logical organisation for a bifunctional pep- 
tidoglycan transglycosylase-transpeptidase would 
be to have the transglycosylase domain within, or 
on the outer surface of, the membrane where it 
acts on its membr~e-ileum disaccharide pen- 
tapeptide substrate, and the transpeptidase extend- 
ing into the periplasm where it can catalyse the 
crosslinking of glycan strands to the preexisting 
peptidoglycan. The transpeptidase domain may 
therefore normally exist within an aqueous en- 
vironment and may be, readily crystallised if 
removed from the transglycosylase domain. Re- 
moval of the NHz-terminus of PBP 3 resulted in at 
least some of the protein being found in the 
cytoplasm but substantial amounts were aIs0 
found in the cell envelope fraction. The instability 
of the protein made further analysis of its solubili- 
ty properties difficult, and further fusions are be- 
ing constructed to see if alteration of the position 
in PBP 3 where the protein is fused to ,&galacto- 
sidase can result in more stable proteins. The pro- 
duction of a smaller, soluble, penicillin-binding 
domain from a high molecular mass PBP .would be 
an attractive prospect for X-ray studies of a killing 
target for ,&lactam antibiotics. 
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